The Heller School for Social Policy and Management
Opioid Policy Research Collaborative

References

  1. Leshner AI, Mancher M. Medications for Opioid Use Disorder Saves Lives. National Academies Press; 2019. https://www.ncbi.nlm.nih.gov/books/NBK538936/   
  2. Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550. https://doi.org/10.1136/bmj.j1550 
  3. Larochelle MR, Bernson D, Land T, et al. Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study. Ann Intern Med. 2018;169(3):137-145. https://www.acpjournals.org/doi/10.7326/M17-3107
  4. Morgan JR, Schackman BR, Weinstein ZM, Walley AY, Linas BP. Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort. Drug Alcohol Depend. 2019;200:34-39. https://doi.org/10.1016/j.drugalcdep.2019.02.031
  5. Wu LT, Zhu H, Swartz MS. Treatment utilization among persons with opioid use disorder in the United States. Drug Alcohol Depend. 2016;169:117-127. https://doi.org/10.1016/j.drugalcdep.2016.10.015
  6. Woodruff J, Bratberg J, Feltus S, et al. Pharmacy-based Methadone: Analysis of Current Laws and Regulations. Brand Univ. Published online November 2024. https://legislativeanalysis.org/wp-content/uploads/2024/11/Pharmacy-based-Methadone.pdf 
  7. Substance Abuse and Mental Health Services Administration. National Substance Use and Mental Health Services Survey (N-SUMHSS) State Profile 2023. Published online 2023. https://www.samhsa.gov/data/sites/default/files/reports/rpt53014/2023-nsumhss-state-profiles.pdf 
  8. The Pew Charitable Trusts. Overview of Opioid Treatment Program Regulations by State. 2022. Accessed June 25, 2025. https://pew.org/3Qw8g8c 
  9. American Society of Addiction Medicine. Addiction Clinicians’ Letter to Congress.; 2023. Accessed December 1, 2025. https://downloads.asam.org/sitefinity-production-blobs/docs/default-source/advocacy/letters-and-comments/methadone-resources/30.03.23_clinician-letter.pdf?sfvrsn=2efcb320_1
  10. American Society of Addiction Medicine. Stakeholders’ Letter to Congress.; 2023. Accessed December 1, 2025. https://downloads.asam.org/sitefinity-production-blobs/docs/default-source/advocacy/letters-and-comments/motaa/08.13.24_motaa-stakeholder-endorsement.pdf?sfvrsn=f66eb4b6_1 
  11. National Coalition to Liberate Methadone, National Survivors Union, NYU Langone Center for Opioid Epidemiology and Policy. Liberating Methadone: A Roadmap for Change Conference Proceedings and Recommendations.; 2024. Accessed February 3, 2025. https://drive.google.com/file/d/1eRwpgfpfuR9Miphk5b7BsHRs4TEeYOBC/view?usp=sharing 
  12. Simon C, Vincent L, Coulter A, et al. The Methadone Manifesto: Treatment Experiences and Policy Recommendations From Methadone Patient Activists. Am J Public Health. 2022;112(S2):S117-S122. https://ajph.aphapublications.org/doi/full/10.2105/AJPH.2021.306665
  13. Wu LT, John WS, Mannelli P, Morse ED, Anderson A, Schwartz RP. Patient perspectives on community pharmacy administered and dispensing of methadone treatment for opioid use disorder: a qualitative study in the U.S. Addict Sci Clin Pract. 2023;18:45. https://doi.org/10.1186/s13722-023-00399-6
  14. Green TC, Dauria EF, Bratberg J, Davis CS, Walley AY. Orienting patients to greater opioid safety: models of community pharmacy-based naloxone. Harm Reduct J. 2015;12(1):25. https://doi.org/10.1186/s12954-015-0058-x 
  15. Community Engaged Research Core of the COBRE on Opioids and Overdose at Rhode Island Hospital. Shaking the Tree of Science: COBRE’s Principles for Community Empowering Research.; 2022.